Nordea Investment Management AB Acquires New Stake in Bioverativ Inc (BIVV)
Nordea Investment Management AB acquired a new position in Bioverativ Inc (NASDAQ:BIVV) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 37,379 shares of the biotechnology company’s stock, valued at approximately $2,133,000.
A number of other institutional investors also recently added to or reduced their stakes in the business. Advisors Asset Management Inc. purchased a new stake in Bioverativ in the 3rd quarter worth approximately $137,000. TCI Wealth Advisors Inc. purchased a new stake in Bioverativ in the 3rd quarter worth approximately $186,000. Canada Pension Plan Investment Board purchased a new stake in Bioverativ in the 3rd quarter worth approximately $194,000. ACG Wealth purchased a new stake in Bioverativ in the 3rd quarter worth approximately $205,000. Finally, Roberts Glore & Co. Inc. IL purchased a new stake in Bioverativ in the 3rd quarter worth approximately $232,000. Institutional investors and hedge funds own 95.23% of the company’s stock.
Bioverativ Inc (BIVV) opened at $50.71 on Friday. Bioverativ Inc has a 52-week low of $40.00 and a 52-week high of $64.41.
Several equities research analysts have commented on the company. Zacks Investment Research upgraded Bioverativ from a “sell” rating to a “hold” rating in a research report on Thursday, August 24th. Morgan Stanley restated an “underweight” rating and issued a $47.00 price objective (up previously from $45.00) on shares of Bioverativ in a research report on Friday, October 6th. Piper Jaffray Companies restated an “overweight” rating and issued a $71.00 price objective on shares of Bioverativ in a research report on Monday, October 23rd. Royal Bank Of Canada began coverage on Bioverativ in a research report on Thursday, September 14th. They set a “sector perform” rating and a $59.00 target price on the stock. Finally, Evercore ISI began coverage on Bioverativ in a research report on Wednesday, August 16th. They set an “in-line” rating and a $58.00 target price on the stock. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Bioverativ presently has a consensus rating of “Hold” and an average price target of $60.93.
COPYRIGHT VIOLATION WARNING: “Nordea Investment Management AB Acquires New Stake in Bioverativ Inc (BIVV)” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.thecerbatgem.com/2017/12/08/nordea-investment-management-ab-acquires-new-stake-in-bioverativ-inc-bivv.html.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Stock Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related stocks with our FREE daily email newsletter.